Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...
The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's ...